Abstract
Infection with the Ebola virus (EBOV) causes an aggressive hemorrhagic disease in humans and nonhuman primates. Traditional approaches, such as vaccination with inactivated virion preparations, have had limited efficacy, whereas immunization with live-attenuated EBOV is not feasible due to the highly lethal nature of the pathogen. This has necessitated the development of other approaches towards an effective EBOV vaccine. Over the past decade, recombinant viruses expressing the EBOV glycoprotein (GP) have constituted the most promising platforms, as evidenced by their ability to protect naïve nonhuman primates from a lethal EBOV challenge. The vesicular stomatitis virus (VSV) is one such vector and is currently progressing through the clinical pipeline. This chapter presents methodologies for the design, cloning, rescue, and preparation of live, recombinant VSV vaccines expressing GP for research purposes.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
CDC.gov (2014) Outbreaks chronology: Ebola virus disease. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html. Accessed 15 Feb 2015
WHO.int (2015) Ebola response roadmap situation report update. http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-20150220?lang=en
CDC.gov (2015) 2014 Ebola outbreak in West Africa—outbreak distribution map. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/distribution-map.html#areas. Accessed 15 Feb 2015
Promedmail.org (2014) Ebola virus disease—ex Africa (27): USA (Texas) Second nurse better, test, quarantine. http://www.promedmail.org/direct.php?id=2910297. Accessed 15 Jan 2015
Promedmail.org (2014) Ebola virus disease—ex Africa (32): Spanish nurse recovered, USA seeks patent. http://www.promedmail.org/direct.php?id=2939861. Accessed 15 Jan 2015
Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8:503–507
Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605–609
Sullivan NJ, Geisbert TW, Geisbert JB, Xu L et al (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681–684
Zahn R, Gillisen G, Roos A, Koning M et al (2012) Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One 7(12):e44115
Stanley DA, Honko AN, Asiedu C, Trefry JC et al (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20:1126–1129
Bukreyev A, Rollin PE, Tate MK, Yang L et al (2007) Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81:6379–6388
Blaney JE, Marzi A, Willet M, Papaneri AB et al (2013) Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9(5):e1003389
Herbert AS, Kuehne AI, Barth JF, Ortiz RA et al (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87:4952–4964
Jones SM, Feldmann H, Stroher U, Geisbert JB et al (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786–790
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB et al (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3(1):e2
Garbutt M, Liebscher R, Wahl-Jensen V, Jones S et al (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78:5458–5465
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Wong, G., Qiu, X. (2016). Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3387-7_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3385-3
Online ISBN: 978-1-4939-3387-7
eBook Packages: Springer Protocols